Business Context and Reporting Period
This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) on March 6, 2026, covering events occurring on March 3, 2026. The filing details the entry into a new supply agreement and an amendment to an existing contract research agreement, both involving related parties.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is an approximate cost increase of $0.6 million related to the amendment of the Contract Research Agreement. Management explicitly states that neither the new Supply Agreement nor the Contract Research Amendment is considered material to the Company's financial condition or results of operations.
Material Changes and Related Party Transactions
- Supply Agreement: Amphastar Nanjing Pharmaceuticals, Inc. (ANP) entered into a five-year agreement with Nanjing Letop Biotechnology Co., Ltd. ("Letop") to manufacture chemical intermediates. ANP has no obligation to purchase a minimum quantity. Payments will be made in Chinese yuan.
- Related Party Status (Letop): Henry Zhang, an immediate family member of CEO Dr. Jack Zhang and Chairman Dr. Mary Luo, beneficially owns a majority of Letop. The Audit Committee approved this transaction.
- Contract Research Amendment: Amphastar amended an agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") to utilize Research Cell Banks for product candidate AMP-105 instead of AMP-107.
- Related Party Status (Hanxin): Dr. Jack Zhang, Dr. Mary Luo, and certain family members beneficially own a majority of Hanxin. Henry Zhang serves as general manager and chairman of Hanxin. The Audit Committee approved this amendment.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the performance of the agreements and expected payments. It warns that actual results may differ due to risks including changes in laws, regulations, and supply chain disruptions. No specific financial guidance or outlook for the fiscal year was provided in this report.
Investor Verification Checklist
- Verify the specific terms and pricing of the Supply Agreement with Letop in Exhibit 10.1, noting that confidential information was redacted.
- Confirm the total cumulative cost of the Contract Research Agreement with Hanxin following the $0.6 million increase.
- Review the Audit Committee's approval documentation for both related party transactions to ensure compliance with internal governance policies.
- Monitor future filings for any materiality reassessment if the volume of purchases from Letop or costs associated with Hanxin increase significantly.